Share Price and Basic Stock Data
Last Updated: May 3, 2025, 9:00 pm
PEG Ratio | -10.02 |
---|
Competitors of Thyrocare Technologies Ltd
Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
---|---|---|---|---|---|---|---|---|---|
NG Industries Ltd | 53.0 Cr. | 158 | 206/145 | 4.37 | 124 | 2.21 % | 6.50 % | 5.63 % | 10.0 |
Global Longlife Hospital and Research Ltd | 24.3 Cr. | 23.2 | 46.4/18.3 | 122 | 25.5 | 0.00 % | 0.98 % | 0.77 % | 10.0 |
Gian Lifecare Ltd | 17.2 Cr. | 16.6 | 27.0/12.1 | 4.20 | 19.2 | 0.00 % | 29.2 % | 24.6 % | 10.0 |
Fortis Malar Hospitals Ltd | 143 Cr. | 76.4 | 98.7/51.0 | 186 | 15.9 | 55.6 % | 3.29 % | 9.12 % | 10.0 |
Family Care Hospitals Ltd | 25.6 Cr. | 4.74 | 9.50/3.40 | 0.67 | 2.67 | 0.00 % | 15.4 % | 24.1 % | 10.0 |
Industry Average | 24,117.43 Cr | 701.59 | 60.72 | 87.90 | 2.67% | 12.25% | 11.61% | 9.08 |
Quarterly Result
Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 110 | 123 | 119 | 125 | 117 | 125 | 124 | 136 | 123 | 141 | 144 | 163 | 153 |
Expenses | 74 | 86 | 85 | 96 | 91 | 102 | 90 | 100 | 92 | 108 | 101 | 114 | 112 |
Operating Profit | 36 | 37 | 34 | 30 | 26 | 23 | 33 | 37 | 31 | 34 | 42 | 49 | 40 |
OPM % | 33% | 30% | 28% | 24% | 22% | 18% | 27% | 27% | 25% | 24% | 29% | 30% | 26% |
Other Income | 1 | 2 | 1 | 1 | 1 | 2 | 0 | 2 | 2 | 3 | 3 | 2 | 4 |
Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
Depreciation | 7 | 9 | 8 | 8 | 9 | 9 | 9 | 9 | 11 | 10 | 9 | 10 | 15 |
Profit before tax | 29 | 29 | 27 | 22 | 18 | 15 | 24 | 28 | 21 | 25 | 35 | 40 | 28 |
Tax % | 22% | 31% | 24% | 35% | 28% | 33% | 31% | 28% | 28% | 23% | 28% | 27% | 32% |
Net Profit | 23 | 20 | 20 | 14 | 13 | 10 | 17 | 20 | 15 | 19 | 25 | 30 | 19 |
EPS in Rs | 4.27 | 3.85 | 3.80 | 2.70 | 2.39 | 1.88 | 3.16 | 3.83 | 2.81 | 3.63 | 4.75 | 5.59 | 3.60 |
Last Updated: February 28, 2025, 4:35 pm
Below is a detailed analysis of the quarterly data for Thyrocare Technologies Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is 153.00 Cr.. The value appears to be declining and may need further review. It has decreased from 163.00 Cr. (Sep 2024) to 153.00 Cr., marking a decrease of 10.00 Cr..
- For Expenses, as of Dec 2024, the value is 112.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 114.00 Cr. (Sep 2024) to 112.00 Cr., marking a decrease of 2.00 Cr..
- For Operating Profit, as of Dec 2024, the value is 40.00 Cr.. The value appears to be declining and may need further review. It has decreased from 49.00 Cr. (Sep 2024) to 40.00 Cr., marking a decrease of 9.00 Cr..
- For OPM %, as of Dec 2024, the value is 26.00%. The value appears to be declining and may need further review. It has decreased from 30.00% (Sep 2024) to 26.00%, marking a decrease of 4.00%.
- For Other Income, as of Dec 2024, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Sep 2024) to 4.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Dec 2024, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.00 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Dec 2024, the value is 15.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.00 Cr. (Sep 2024) to 15.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Dec 2024, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 40.00 Cr. (Sep 2024) to 28.00 Cr., marking a decrease of 12.00 Cr..
- For Tax %, as of Dec 2024, the value is 32.00%. The value appears to be increasing, which may not be favorable. It has increased from 27.00% (Sep 2024) to 32.00%, marking an increase of 5.00%.
- For Net Profit, as of Dec 2024, the value is 19.00 Cr.. The value appears to be declining and may need further review. It has decreased from 30.00 Cr. (Sep 2024) to 19.00 Cr., marking a decrease of 11.00 Cr..
- For EPS in Rs, as of Dec 2024, the value is 3.60. The value appears to be declining and may need further review. It has decreased from 5.59 (Sep 2024) to 3.60, marking a decrease of 1.99.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: March 6, 2025, 2:35 pm
Metric | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 134 | 150 | 180 | 235 | 298 | 332 | 370 | 401 | 474 | 562 | 486 | 524 | 600 |
Expenses | 71 | 81 | 109 | 140 | 182 | 193 | 222 | 233 | 304 | 330 | 371 | 388 | 435 |
Operating Profit | 64 | 69 | 71 | 95 | 115 | 139 | 148 | 168 | 171 | 232 | 115 | 136 | 165 |
OPM % | 47% | 46% | 40% | 40% | 39% | 42% | 40% | 42% | 36% | 41% | 24% | 26% | 27% |
Other Income | 18 | 7 | 13 | 6 | -16 | 21 | 14 | -35 | 12 | 7 | 5 | 6 | 12 |
Interest | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 3 | 5 | 5 | 3 |
Depreciation | 3 | 6 | 11 | 11 | 12 | 12 | 14 | 20 | 21 | 28 | 34 | 39 | 45 |
Profit before tax | 78 | 69 | 73 | 89 | 87 | 148 | 147 | 112 | 161 | 207 | 81 | 98 | 128 |
Tax % | 27% | 33% | 33% | 34% | 46% | 35% | 35% | 29% | 26% | 27% | 30% | 28% | |
Net Profit | 57 | 46 | 49 | 59 | 47 | 96 | 95 | 79 | 120 | 152 | 57 | 71 | 93 |
EPS in Rs | 52.04 | 42.28 | 9.75 | 10.94 | 8.69 | 17.87 | 18.04 | 15.01 | 22.65 | 28.74 | 10.76 | 13.43 | 17.57 |
Dividend Payout % | 0% | 0% | 157% | 91% | 115% | 56% | 111% | 33% | 110% | 52% | 167% | 134% |
YoY Net Profit Growth
Year | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
---|---|---|---|---|---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | -19.30% | 6.52% | 20.41% | -20.34% | 104.26% | -1.04% | -16.84% | 51.90% | 26.67% | -62.50% | 24.56% |
Change in YoY Net Profit Growth (%) | 0.00% | 25.82% | 13.89% | -40.75% | 124.59% | -105.30% | -15.80% | 68.74% | -25.23% | -89.17% | 87.06% |
Thyrocare Technologies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | 10% |
3 Years: | 4% |
TTM: | 21% |
Compounded Profit Growth | |
---|---|
10 Years: | 7% |
5 Years: | -2% |
3 Years: | -14% |
TTM: | 39% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 13% |
3 Years: | 6% |
1 Year: | 42% |
Return on Equity | |
---|---|
10 Years: | 20% |
5 Years: | 20% |
3 Years: | 14% |
Last Year: | 18% |
Last Updated: Unknown
Balance Sheet
Last Updated: November 14, 2024, 6:42 pm
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 11 | 11 | 51 | 54 | 54 | 54 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
Reserves | 149 | 195 | 229 | 322 | 364 | 400 | 403 | 325 | 393 | 468 | 468 | 461 | 426 |
Borrowings | 25 | 25 | 0 | 0 | 0 | 0 | 0 | 9 | 10 | 21 | 21 | 39 | 17 |
Other Liabilities | 11 | 14 | 14 | 39 | 26 | 31 | 32 | 55 | 73 | 55 | 70 | 68 | 84 |
Total Liabilities | 197 | 246 | 293 | 414 | 444 | 485 | 488 | 442 | 528 | 597 | 612 | 620 | 581 |
Fixed Assets | 75 | 87 | 83 | 93 | 89 | 103 | 108 | 112 | 119 | 149 | 157 | 159 | 151 |
CWIP | 10 | 6 | 6 | 1 | 2 | 0 | 1 | 4 | 8 | 2 | 1 | 1 | 1 |
Investments | 77 | 119 | 162 | 266 | 299 | 315 | 289 | 239 | 274 | 259 | 274 | 291 | 236 |
Other Assets | 34 | 33 | 42 | 55 | 54 | 68 | 89 | 88 | 127 | 186 | 180 | 169 | 193 |
Total Assets | 197 | 246 | 293 | 414 | 444 | 485 | 488 | 442 | 528 | 597 | 612 | 620 | 581 |
Below is a detailed analysis of the balance sheet data for Thyrocare Technologies Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2024, the value is ₹53.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 53.00 Cr..
- For Reserves, as of Sep 2024, the value is ₹426.00 Cr.. The value appears to be declining and may need further review. It has decreased from 461.00 Cr. (Mar 2024) to ₹426.00 Cr., marking a decrease of 35.00 Cr..
- For Borrowings, as of Sep 2024, the value is ₹17.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 39.00 Cr. (Mar 2024) to ₹17.00 Cr., marking a decrease of 22.00 Cr..
- For Other Liabilities, as of Sep 2024, the value is ₹84.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 68.00 Cr. (Mar 2024) to ₹84.00 Cr., marking an increase of 16.00 Cr..
- For Total Liabilities, as of Sep 2024, the value is ₹581.00 Cr.. The value appears to be improving (decreasing). It has decreased from 620.00 Cr. (Mar 2024) to ₹581.00 Cr., marking a decrease of 39.00 Cr..
- For Fixed Assets, as of Sep 2024, the value is ₹151.00 Cr.. The value appears to be declining and may need further review. It has decreased from 159.00 Cr. (Mar 2024) to ₹151.00 Cr., marking a decrease of 8.00 Cr..
- For CWIP, as of Sep 2024, the value is ₹1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.00 Cr..
- For Investments, as of Sep 2024, the value is ₹236.00 Cr.. The value appears to be declining and may need further review. It has decreased from 291.00 Cr. (Mar 2024) to ₹236.00 Cr., marking a decrease of 55.00 Cr..
- For Other Assets, as of Sep 2024, the value is ₹193.00 Cr.. The value appears strong and on an upward trend. It has increased from 169.00 Cr. (Mar 2024) to ₹193.00 Cr., marking an increase of 24.00 Cr..
- For Total Assets, as of Sep 2024, the value is ₹581.00 Cr.. The value appears to be declining and may need further review. It has decreased from 620.00 Cr. (Mar 2024) to ₹581.00 Cr., marking a decrease of 39.00 Cr..
Notably, the Reserves (426.00 Cr.) exceed the Borrowings (17.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | 39.00 | 44.00 | 71.00 | 95.00 | 115.00 | 139.00 | 148.00 | 159.00 | 161.00 | 211.00 | 94.00 | 97.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 9 | 12 | 9 | 11 | 7 | 10 | 11 | 14 | 34 | 60 | 63 | 28 |
Inventory Days | 54 | 54 | 47 | 54 | 64 | 66 | 54 | 60 | 50 | 54 | 63 | 106 |
Days Payable | 2 | 13 | 5 | 8 | 4 | 23 | 19 | 62 | 48 | 30 | 52 | 83 |
Cash Conversion Cycle | 61 | 53 | 51 | 57 | 68 | 53 | 46 | 12 | 37 | 84 | 74 | 51 |
Working Capital Days | 19 | 22 | 52 | 15 | 28 | 11 | 4 | -9 | 9 | 49 | 39 | 25 |
ROCE % | 50% | 33% | 27% | 27% | 29% | 33% | 31% | 36% | 37% | 41% | 15% | 18% |
Mutual Fund Holdings
Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
---|---|---|---|---|---|---|
Nippon India Small Cap Fund | 1,778,165 | 0.24 | 108.49 | 1,778,165 | 2025-04-22 17:25:17 | 0% |
Nippon India Pharma Fund | 1,765,838 | 1.56 | 107.74 | 1,765,838 | 2025-04-22 15:19:42 | 0% |
ICICI Prudential India Opportunities Fund | 1,184,131 | 0.45 | 72.25 | 1,184,131 | 2025-04-22 17:25:17 | 0% |
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 765,047 | 1.31 | 46.68 | 765,047 | 2025-04-22 15:19:42 | 0% |
Nippon India Retirement Fund - Wealth Creation Scheme | 321,903 | 0.67 | 19.64 | 321,903 | 2025-04-22 17:25:18 | 0% |
ICICI Prudential Bharat Consumption Fund | 230,281 | 0.64 | 14.05 | 230,281 | 2025-04-22 17:25:18 | 0% |
ICICI Prudential Retirement Fund - Pure Equity | 12,631 | 0.14 | 0.77 | 12,631 | 2025-04-22 15:19:42 | 0% |
ICICI Prudential Retirement Fund - Hybrid Aggressive | 1,186 | 0.02 | 0.07 | 1,186 | 2025-04-22 15:19:42 | 0% |
Motilal Oswal S&P BSE Healthcare ETF | 163 | 0.1 | 0.01 | 163 | 2025-04-22 17:25:18 | 0% |
Key Financial Ratios
Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
---|---|---|---|---|---|
FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Basic EPS (Rs.) | 13.42 | 12.16 | 33.30 | 21.41 | 16.74 |
Diluted EPS (Rs.) | 13.40 | 12.14 | 33.25 | 21.37 | 16.71 |
Cash EPS (Rs.) | 21.93 | 19.25 | 39.73 | 27.14 | 22.67 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 99.65 | 101.12 | 99.54 | 80.81 | 69.39 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 99.65 | 101.12 | 99.54 | 80.81 | 69.39 |
Revenue From Operations / Share (Rs.) | 108.00 | 99.50 | 111.32 | 93.55 | 82.18 |
PBDIT / Share (Rs.) | 27.72 | 24.27 | 49.93 | 34.74 | 34.11 |
PBIT / Share (Rs.) | 18.85 | 16.96 | 43.53 | 29.02 | 28.07 |
PBT / Share (Rs.) | 18.05 | 16.51 | 43.08 | 28.85 | 26.48 |
Net Profit / Share (Rs.) | 13.05 | 11.94 | 33.33 | 21.41 | 16.63 |
NP After MI And SOA / Share (Rs.) | 13.36 | 12.16 | 33.30 | 21.40 | 16.73 |
PBDIT Margin (%) | 25.66 | 24.39 | 44.85 | 37.13 | 41.50 |
PBIT Margin (%) | 17.44 | 17.04 | 39.10 | 31.01 | 34.15 |
PBT Margin (%) | 16.71 | 16.59 | 38.70 | 30.83 | 32.21 |
Net Profit Margin (%) | 12.08 | 11.99 | 29.94 | 22.89 | 20.23 |
NP After MI And SOA Margin (%) | 12.37 | 12.22 | 29.91 | 22.87 | 20.35 |
Return on Networth / Equity (%) | 13.43 | 12.04 | 33.45 | 26.48 | 24.11 |
Return on Capital Employeed (%) | 18.03 | 16.15 | 42.39 | 34.03 | 38.11 |
Return On Assets (%) | 10.98 | 10.17 | 28.98 | 20.73 | 18.77 |
Long Term Debt / Equity (X) | 0.02 | 0.00 | 0.00 | 0.00 | 0.01 |
Total Debt / Equity (X) | 0.04 | 0.00 | 0.00 | 0.00 | 0.01 |
Asset Turnover Ratio (%) | 0.89 | 0.79 | 0.98 | 0.94 | 0.87 |
Current Ratio (X) | 3.08 | 3.54 | 4.18 | 2.50 | 1.86 |
Quick Ratio (X) | 2.55 | 3.18 | 3.80 | 2.26 | 1.61 |
Inventory Turnover Ratio (X) | 4.38 | 5.82 | 6.80 | 7.44 | 6.03 |
Dividend Payout Ratio (NP) (%) | 134.63 | 123.29 | 45.02 | 46.69 | 149.32 |
Dividend Payout Ratio (CP) (%) | 80.89 | 76.98 | 37.76 | 36.84 | 109.71 |
Earning Retention Ratio (%) | -34.63 | -23.29 | 54.98 | 53.31 | -49.32 |
Cash Earning Retention Ratio (%) | 19.11 | 23.02 | 62.24 | 63.16 | -9.71 |
Interest Coverage Ratio (X) | 34.95 | 54.67 | 111.45 | 211.14 | 97.43 |
Interest Coverage Ratio (Post Tax) (X) | 17.45 | 27.89 | 75.40 | 131.14 | 52.06 |
Enterprise Value (Cr.) | 3118.27 | 2246.85 | 4079.23 | 4758.17 | 2609.92 |
EV / Net Operating Revenue (X) | 5.45 | 4.27 | 6.93 | 9.62 | 6.01 |
EV / EBITDA (X) | 21.24 | 17.49 | 15.44 | 25.90 | 14.48 |
MarketCap / Net Operating Revenue (X) | 5.48 | 4.32 | 6.95 | 9.65 | 6.03 |
Retention Ratios (%) | -34.63 | -23.29 | 54.97 | 53.30 | -49.32 |
Price / BV (X) | 5.95 | 4.26 | 7.77 | 11.17 | 7.14 |
Price / Net Operating Revenue (X) | 5.48 | 4.32 | 6.95 | 9.65 | 6.03 |
EarningsYield | 0.02 | 0.02 | 0.04 | 0.02 | 0.03 |
After reviewing the key financial ratios for Thyrocare Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 13.42. This value is within the healthy range. It has increased from 12.16 (Mar 23) to 13.42, marking an increase of 1.26.
- For Diluted EPS (Rs.), as of Mar 24, the value is 13.40. This value is within the healthy range. It has increased from 12.14 (Mar 23) to 13.40, marking an increase of 1.26.
- For Cash EPS (Rs.), as of Mar 24, the value is 21.93. This value is within the healthy range. It has increased from 19.25 (Mar 23) to 21.93, marking an increase of 2.68.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 99.65. It has decreased from 101.12 (Mar 23) to 99.65, marking a decrease of 1.47.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 99.65. It has decreased from 101.12 (Mar 23) to 99.65, marking a decrease of 1.47.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 108.00. It has increased from 99.50 (Mar 23) to 108.00, marking an increase of 8.50.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 27.72. This value is within the healthy range. It has increased from 24.27 (Mar 23) to 27.72, marking an increase of 3.45.
- For PBIT / Share (Rs.), as of Mar 24, the value is 18.85. This value is within the healthy range. It has increased from 16.96 (Mar 23) to 18.85, marking an increase of 1.89.
- For PBT / Share (Rs.), as of Mar 24, the value is 18.05. This value is within the healthy range. It has increased from 16.51 (Mar 23) to 18.05, marking an increase of 1.54.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 13.05. This value is within the healthy range. It has increased from 11.94 (Mar 23) to 13.05, marking an increase of 1.11.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 13.36. This value is within the healthy range. It has increased from 12.16 (Mar 23) to 13.36, marking an increase of 1.20.
- For PBDIT Margin (%), as of Mar 24, the value is 25.66. This value is within the healthy range. It has increased from 24.39 (Mar 23) to 25.66, marking an increase of 1.27.
- For PBIT Margin (%), as of Mar 24, the value is 17.44. This value is within the healthy range. It has increased from 17.04 (Mar 23) to 17.44, marking an increase of 0.40.
- For PBT Margin (%), as of Mar 24, the value is 16.71. This value is within the healthy range. It has increased from 16.59 (Mar 23) to 16.71, marking an increase of 0.12.
- For Net Profit Margin (%), as of Mar 24, the value is 12.08. This value exceeds the healthy maximum of 10. It has increased from 11.99 (Mar 23) to 12.08, marking an increase of 0.09.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 12.37. This value is within the healthy range. It has increased from 12.22 (Mar 23) to 12.37, marking an increase of 0.15.
- For Return on Networth / Equity (%), as of Mar 24, the value is 13.43. This value is below the healthy minimum of 15. It has increased from 12.04 (Mar 23) to 13.43, marking an increase of 1.39.
- For Return on Capital Employeed (%), as of Mar 24, the value is 18.03. This value is within the healthy range. It has increased from 16.15 (Mar 23) to 18.03, marking an increase of 1.88.
- For Return On Assets (%), as of Mar 24, the value is 10.98. This value is within the healthy range. It has increased from 10.17 (Mar 23) to 10.98, marking an increase of 0.81.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 23) to 0.02, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.04. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 0.04, marking an increase of 0.04.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.89. It has increased from 0.79 (Mar 23) to 0.89, marking an increase of 0.10.
- For Current Ratio (X), as of Mar 24, the value is 3.08. This value exceeds the healthy maximum of 3. It has decreased from 3.54 (Mar 23) to 3.08, marking a decrease of 0.46.
- For Quick Ratio (X), as of Mar 24, the value is 2.55. This value exceeds the healthy maximum of 2. It has decreased from 3.18 (Mar 23) to 2.55, marking a decrease of 0.63.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 4.38. This value is within the healthy range. It has decreased from 5.82 (Mar 23) to 4.38, marking a decrease of 1.44.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 134.63. This value exceeds the healthy maximum of 50. It has increased from 123.29 (Mar 23) to 134.63, marking an increase of 11.34.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 80.89. This value exceeds the healthy maximum of 50. It has increased from 76.98 (Mar 23) to 80.89, marking an increase of 3.91.
- For Earning Retention Ratio (%), as of Mar 24, the value is -34.63. This value is below the healthy minimum of 40. It has decreased from -23.29 (Mar 23) to -34.63, marking a decrease of 11.34.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 19.11. This value is below the healthy minimum of 40. It has decreased from 23.02 (Mar 23) to 19.11, marking a decrease of 3.91.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 34.95. This value is within the healthy range. It has decreased from 54.67 (Mar 23) to 34.95, marking a decrease of 19.72.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 17.45. This value is within the healthy range. It has decreased from 27.89 (Mar 23) to 17.45, marking a decrease of 10.44.
- For Enterprise Value (Cr.), as of Mar 24, the value is 3,118.27. It has increased from 2,246.85 (Mar 23) to 3,118.27, marking an increase of 871.42.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 5.45. This value exceeds the healthy maximum of 3. It has increased from 4.27 (Mar 23) to 5.45, marking an increase of 1.18.
- For EV / EBITDA (X), as of Mar 24, the value is 21.24. This value exceeds the healthy maximum of 15. It has increased from 17.49 (Mar 23) to 21.24, marking an increase of 3.75.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 5.48. This value exceeds the healthy maximum of 3. It has increased from 4.32 (Mar 23) to 5.48, marking an increase of 1.16.
- For Retention Ratios (%), as of Mar 24, the value is -34.63. This value is below the healthy minimum of 30. It has decreased from -23.29 (Mar 23) to -34.63, marking a decrease of 11.34.
- For Price / BV (X), as of Mar 24, the value is 5.95. This value exceeds the healthy maximum of 3. It has increased from 4.26 (Mar 23) to 5.95, marking an increase of 1.69.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 5.48. This value exceeds the healthy maximum of 3. It has increased from 4.32 (Mar 23) to 5.48, marking an increase of 1.16.
- For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Thyrocare Technologies Ltd:
- Net Profit Margin: 12.08%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.03% (Industry Average ROCE: 12.25%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.43% (Industry Average ROE: 11.61%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 17.45
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.55
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 49.6 (Industry average Stock P/E: 60.72)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.04
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.08%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Hospitals & Medical Services | D/37-1, TTC Industrial Area, New Mumbai Maharashtra 400703 | investor_relations@thyrocare.com http://www.thyrocare.com |
Management | |
---|---|
Name | Position Held |
Mr. Rahul Guha | Managing Director & CEO |
Mr. Dharmil Sheth | Non Executive Director |
Mr. Hardik Dedhia | Non Executive Director |
Mr. Dhaval Shah | Non Executive Director |
Mr. Gopalkrishna Shivram Hegde | Independent Director |
Dr. Indumati Gopinathan | Independent Director |
Dr. Neetin S Desai | Independent Director |
Dr. Prapti Gilada | Independent Director |
Dr. Harshil Vora | Independent Director |
Mr. Nishant A Shah | Independent Director |
Mr. Anandh Sundar | Independent Director |
FAQ
What is the intrinsic value of Thyrocare Technologies Ltd?
Thyrocare Technologies Ltd's intrinsic value (as of 03 May 2025) is ₹744.06 — 16.96% lower the current market price of 896.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,750 Cr. market cap, FY2025-2026 high/low of ₹1,055/571, reserves of 426 Cr, and liabilities of 581 Cr.
What is the Market Cap of Thyrocare Technologies Ltd?
The Market Cap of Thyrocare Technologies Ltd is 4,750 Cr..
What is the current Stock Price of Thyrocare Technologies Ltd as on 03 May 2025?
The current stock price of Thyrocare Technologies Ltd as on 03 May 2025 is 896.
What is the High / Low of Thyrocare Technologies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Thyrocare Technologies Ltd stocks is ₹1,055/571.
What is the Stock P/E of Thyrocare Technologies Ltd?
The Stock P/E of Thyrocare Technologies Ltd is 49.6.
What is the Book Value of Thyrocare Technologies Ltd?
The Book Value of Thyrocare Technologies Ltd is 101.
What is the Dividend Yield of Thyrocare Technologies Ltd?
The Dividend Yield of Thyrocare Technologies Ltd is 2.01 %.
What is the ROCE of Thyrocare Technologies Ltd?
The ROCE of Thyrocare Technologies Ltd is 27.6 %.
What is the ROE of Thyrocare Technologies Ltd?
The ROE of Thyrocare Technologies Ltd is 18.2 %.
What is the Face Value of Thyrocare Technologies Ltd?
The Face Value of Thyrocare Technologies Ltd is 10.0.